openPR Logo
Press release

Next Generation Antibody Therapies Market Size, Status and Forecast to 2025

03-01-2018 12:07 PM CET | Health & Medicine

Press release from: Transparency Market Research

Next Generation Antibody Therapies Market Size, Status

Antibody therapy aka immunotherapy involves using antibodies that have been created in a laboratory to attack an antigen on a cancer cell. Antibody therapy either works independently, with chemotherapy, or is delivered with other therapies.

Immunotherapy is a targeted therapy which is preferred over chemotherapy and radiotherapy as it is more precise, and thus reduces impact on normal cells. Due to this, antibody production has attracted the attention of researchers across the world. Research and development is also underway to create antibody fragments that only attack target cells, and do not trigger immune response unlike full body antibody.

As per the study presented by research analysts, the worldwide Next Generation Antibody Therapies Market could be segregated based on type of antibody, end-user, application, and region. Oncology, autoimmune diseases, and others are the segments based on application that could classify the next generation antibody therapies market.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32147

The global market for next generation antibody therapies market is likely to display a double digit growth rate on the back of increasing efforts by biotechnology and pharmaceutical companies as well as research laboratories for the development of new antibodies. The new antibodies are being developed to treat diseases such as rheumatoid arthritis, cancer, and other chronic diseases.

Extensive research activities have led to the development of more than 30 immunoglobulin and their derivatives that have received approval for various indications. The antibody drugs that have received approval are used to treat diseases that affect a large patient pool, and also for indications that are subject to special regulatory procedures.

Antibody production is gaining the attention of researchers owing to several advantages such as high efficacy for several disease indication, wider therapeutic window, and easy development process.

Furthermore, research for the development of antibody drug conjugates is underway to boost the market in the upcoming years.

However, high cost of production of antibody drugs and limited commercial availability of antibody drug conjugates is posing a challenge to the growth of next generation antibody therapies market. Moreover, antibody drugs are subject to stringent mandates that are laid down by regulatory bodies such as the U.S. FDA.

The mounting volume of research initiatives on antibodies carried out by pharmaceutical and biotechnology companies is the key factor behind the dominance of North America next generation antibody therapies market. North America being a traditional region for research activities also accounts for its lead position.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=32147

Europe is the second-leading market for next generation antibody therapies market as it is home to some world’s leading biotechnology and pharmaceutical companies.

Powered by growth in China and India, Asia Pacific is emerging as a key market for next generation antibody therapies market. This is mainly because of rising incidence of cancer and other chronic diseases, and a large population to conduct clinical trials. Further, increasing number of R&D initiatives and cost efficient research services are contributing to the growth of Asia Pacific next generation antibody therapies market.

Prominent players in the global next generation antibody therapies market include Amgen Inc., Bristol-Myers Squib Company, F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co. Ltd., Pfizer Inc., Xencor Inc., AstraZeneca plc, Bayer AG, Genmab A/S, ImmunoGen Inc., and Seattle Genetics Inc.

View Report -

https://www.transparencymarketresearch.com/next-generation-antibody-therapies-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Next Generation Antibody Therapies Market Size, Status and Forecast to 2025 here

News-ID: 962466 • Views: 112

More Releases from Transparency Market Research

Wearable EEG Devices Market: Growing incidences of Neurovascular Disorders is Dr …
According to new market research titled 'Wearable EEG Devices Market to 2027 - Global Analysis and Forecasts by Channel and Application.' The global wearable EEG devices market is expected to reach US$ 1,556.35 Mn in 2027 from US$ 745.05 Mn in 2018. The market is projected to grow with a CAGR of 8.7% from 2019-2027. The report provides trends prevailing in the global wearable EEG devices market and the factors
Decentralized Electricity Generation Market - Global Industry Analysis, Share, G …
Global Decentralized Electricity Generation Market: Overview With the increasing installation of smart grids and the rising number of electricity generation resources, the power generation industry has been undergoing a significant change over the recent past. The modification in the grid structure, which permits decentralization of electricity generation, is acting as the main driving force behind the substantial growth of the global market for decentralized electricity generation. The main objective of this research
Global Sucralose Market Outlook In The Developed And Emerging Industry
Sucralose Market Overview Sugar substitute market is witnessing an increasing demand driven by the increasing sales of various sugar substitutes such as natural sweeteners and artificial sweeteners. Sucralose, an artificial sweetener used as a sugar substitute is highly preferred by consumers owing to its zero calorie attribute. Though sucralose is 600 times sweeter than sugar but interestingly it is not identified as the carbohydrate by the human body. Sucralose has its
Flavored Syrup Market - Growth Powered with Latest Development Scenario & Influe …
Flavored Syrup Market Introduction Global syrup market is witnessing a significant demand generated by the food and beverage industry. Consumers' increasing preference for different and personalized flavors in food has driven the syrup manufacturers to produce a wide range of flavored syrups. Flavored syrups contain artificial or natural flavorings mixed along with sugar and water. Obtain Report Details @ https://www.transparencymarketresearch.com/flavored-syrup-market.html Increasing demand of flavored syrups especially among the consumers contributes to the

All 5 Releases


More Releases for Antibody

Global Antibody Drug Conjugates Market Insights, Forecast
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement
Procalcitonin Antibody Market Opportunity Analysis, 2018 - 2026
Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, and belongs to calcitonin (CT) superfamily of peptides. Procalcitonin is a 116 amino acid peptide that has an estimated molecular weight of 14.5 kDa. It can be segregated into three parts, namely immature calcitonin, calcitonin carboxyl-terminus peptide-1, and amino terminus of the PCT region. Procalcitonin was first classified by Bernard Roos and Leonard J. Deftos in the early 1970s. Procalcitonin
Procalcitonin Antibody Market
Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E.coli Scope of the Report: This report focuses on the Procalcitonin
Global Combination Antibody Therapy Market | MarketResearchReports.biz
Latest industry research report on: Global Combination Antibody Therapy Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts In its recently published report titled Combination Antibody Therapy Market: Global Industry Analysis and Forecast, 2016-2024, Persistence Market Research reviews the global combination antibody therapy market for an eight year forecast period (2016 2024). This research report provides a detailed analysis of the global combination antibody therapy market
Antibody Drug Conjugate Market Opportunity Analysis
Ever since the first attempt in the 1980's to use antibody-based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the
Global Antibody Drug Conjugate Market & Pipeline Insight2020
Pharmaceutical companies are trying to develop better therapeutics in order to overcome large unmet medical necessities. Currently available therapeutics suffers from various caveats like low specificity, low potency and severe adverse effects. This scenario has caused the pharmaceutical companies to develop therapeutics that can succeed these limitations. They have been able to overcome these problems and improve their medical conditions by commercializing ADC. They are rapidly gaining acceptance across the